Everything below concerns N-terminal modification. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Surprisingly, the saffron retained its distinctive odour even after more than 500 years of submersion in the Baltic Sea. The Essex town of Saffron Walden, named for its new specialty crop, emerged as a prime saffron growing and trading centre in the 16th and 17th centuries but cultivation there was abandoned; saffron was re-introduced around 2013 as well as other parts of the UK (Cheshire).
Following decades of struggle, the Chinese Communist Party under Mao Zedong defeated Chiang Kai-shek's National Revolutionary Army and established a new Marxist–Leninist state in mainland China in 1949, the Nationalist government leaders and much of the Republic of China's upper class fled to Taiwan. Before this, Stalin had in fact supported greatly Chiang Kai-shek's party, while giving help to the CCP in the same time. The United States had tried in 1945–1947 to bring the Nationalists and Communists together in a coalition, but had no success. The conflict was hence not a typical aspect of the Cold War between US and USSR until the 1950s. As the Korean War broke out, US started to provide a larger support to the Nationalist China on the island Taiwan. On the other hand, Communist China came to the North Korea's aid in the Korean War in late 1950, pushed back the UN force and escalated the hostility towards the US.
==== 1.C Pore-forming toxins (proteins and peptides) ==== 1.C.3 α-Hemolysin (αHL) family 1.C.4 Aerolysin family 1.C.5 ε-toxin family 1.C.11 RTX-toxin superfamily 1.C.12 Membrane attack complex/perforin superfamily 1.C.13 Leukocidin family 1.C.14 Cytohemolysin (CHL) family 1.C.39 Thiol-activated cholesterol-dependent cytolysin family 1.C.43 Lysenin family 1.C.56 Pseudomonas syringae HrpZ cation channel family 1.C.57 Clostridial cytotoxin family 1.C.58 The Microcin E492/C24 (Microcin E492) Family 1.C.74 Snake cytotoxin (SCT) family 1.C.97 Pleurotolysin pore-forming family
Lymphocytosis is an increase in the number or proportion of lymphocytes in the blood. Absolute lymphocytosis is the condition where there is an increase in the lymphocyte count beyond the normal range while relative lymphocytosis refers to the condition where the proportion of lymphocytes relative to white blood cell count is above the normal range. In adults, absolute lymphocytosis is present when the lymphocyte count is greater than 5000 per microliter (5.0 billion/L), in older children greater than 7000 per microliter and in infants greater than 9000 per microliter. Lymphocytes normally represent 20% to 40% of circulating white blood cells. When the percentage of lymphocytes exceeds 40%, it is recognized as relative lymphocytosis.
Sources: en.wikipedia.org
He received the Hirschmann Award in Peptide Chemistry from the American Chemical Societyin 1994, the (inaugural) Kaiser Award from the Protein Society in 2002, the du Vigneaud Award from the American Peptide Society (2004), the 2009 Merrifield award from the American Peptide Society, the Rudinger Medal from the European Peptide Society (2010), the Akabori Medal from the Japanese Peptide Society (2010), the Bader Award in Bioorganic Chemistry (2011) from the American Chemical Society, the Leach Medal from the Lorne Protein Conference (2013), the Prelog Medal from the ETH Zurich (2017), the (inaugural) Scoffone Award from the Italian Peptide Society (2018), and the Meienhofer Award of the Boulder Peptide Society (2022). Dr. Kent is Honorary Fellow of the Royal Society of New Zealand. He was elected Fellow of the American Association for the Advancement of Science in 2000, and Fellow of the Royal Society of Chemistry in 2008. In May 2016 the Journal of Peptide Science, edited by Luis_Moroder, published a Festschrift in celebration of Stephen Kent's 70th birthday. In 2022, Stephen Kent's scientific autobiography was published as the first English language contribution to the book series Lives-in-Chemistry; this series is steered by an Advisory Board appointed by the Executive Committee of the Fachgruppe Geschichte der Chemie (History of Chemistry Division) of the Gesellschaft Deutscher Chemiker (GDCh).
This rescheduling makes medical cannabis legal for medicinal use when dispensed by licensed dispensaries to individuals with a state issued medical marijuana card, including CBD derived from marijuana; once the broader rescheduling is complete, it should allow it to be prescribed by licensed physicians who are also licensed by the DEA to prescribe controlled substances. However, as cannabis is still a controlled substance, recreational use of cannabis-derived CBD with a THC concentration of >0.3% is still illegal under federal law.
Cairnes School of Business & Economics. Several new buildings were constructed on the university campus in the 1970s and were designed by architects Scott Tallon Walker. The 1990s also saw considerable development, including the conversion of an old munitions factory into a student centre. Under the early 21st-century Presidency of Iognáid G. Ó Muircheartaigh, the university announced details of plans to make the university a "campus of the future" at a cost of around €400 million. Ó Muircheartaigh's successor James J. Browne continued and implemented that plan. Under the Universities Act 1997, the name of University College, Galway, was changed to National University of Ireland, Galway (NUI Galway), and it became a university in its own right, as a constituent university of the National University of Ireland (NUI). The university had hoped to change its name to University of Galway, but had received legal advice that this was not possible under the provisions of the Act. Visiting the university in 2003, on what was to be his last visit to Ireland, Nelson Mandela condemned U.S. foreign policy and received an honorary doctorate from the NUI Chancellor, Garret FitzGerald. 21st-century developments include a state-of-the-art University Sports Centre (Ionad Spóirt), Áras Moyola, J.E. Cairnes School of Business & Economics, the Alice Perry Engineering Building, the BioSciences Research Building, the Life Course Institute, the Lambe Institute and the O'Donoghue Centre for Drama, Theatre and Performance, and the Human Biology Building.
=== Close states === The seven swing states in the 2024 election were the Rust Belt states of Wisconsin, Michigan, and Pennsylvania, as well as the Sun Belt states of Arizona, Georgia, Nevada, and North Carolina. States where the margin of victory was under 1 percentage point (10 electoral votes; all won by Trump):
Lenton Parr AM, founding dean, 1972–1975 William Kelly, 1975–1982 John Walker, 1982–1985 Gareth Sansom, 1986–1991 Norman Baggaley, 1991–1997 Mostyn Bramley-Moore, 1997–1999 Su Baker, 2000–2010 Barry Conyngham, 2010–2021 Marie Sierra, 2021–present
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.